Adamas Pharma, LLC
Records under this name other than the patents Adamas Pharma, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,389,578 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 8,058,291 | Methods and Compositions for the Treatment of Cns-Related Conditions now held by Adamas Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 8,168,209 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject now held by Adamas Pharmaceuticals, Inc. Term ended Term ended Jul 18, 2026 · High confidence | Term ended | Term ended Jul 18, 2026 | High confidence |
| US 8,796,337 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Term ended Nov 23, 2025 · High confidence | Term ended | Term ended Nov 23, 2025 | High confidence |
| US 8,889,740 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Ended no later than Nov 23, 2025 · Medium confidence | Term ended | Ended no later than Nov 23, 2025 | Medium confidence |
| US 8,895,614 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Ended no later than Nov 23, 2025 · Medium confidence | Term ended | Ended no later than Nov 23, 2025 | Medium confidence |
| US 8,895,615 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Ended no later than Nov 23, 2025 · Medium confidence | Term ended | Ended no later than Nov 23, 2025 | Medium confidence |
| US 8,895,616 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Term ended Nov 23, 2025 · High confidence | Term ended | Term ended Nov 23, 2025 | High confidence |
| US 8,895,617 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Ended no later than Nov 23, 2025 · Medium confidence | Term ended | Ended no later than Nov 23, 2025 | Medium confidence |
| US 8,895,618 | Composition and Method for Treating Neurological Disease now held by Adamas Pharmaceuticals, Inc. Term ended Ended no later than Nov 23, 2025 · Medium confidence | Term ended | Ended no later than Nov 23, 2025 | Medium confidence |